Jefferies Group Lowers Hikma Pharmaceuticals (HIK) to Underperform

Hikma Pharmaceuticals (LON:HIK) was downgraded by investment analysts at Jefferies Group to an “underperform” rating in a report issued on Wednesday. They currently have a GBX 895 ($12.14) price objective on the stock, down from their prior price objective of GBX 1,074 ($14.56). Jefferies Group’s target price suggests a potential downside of 11.40% from the company’s current price.

Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Hikma Pharmaceuticals in a research note on Friday, September 29th. Peel Hunt reaffirmed a “hold” rating and issued a GBX 1,390 ($18.85) target price on shares of Hikma Pharmaceuticals in a research note on Thursday, November 9th. dropped their target price on shares of Hikma Pharmaceuticals from GBX 1,060 ($14.37) to GBX 865 ($11.73) and set a “reduce” rating for the company in a research note on Friday, November 10th. Stifel Nicolaus dropped their target price on shares of Hikma Pharmaceuticals from GBX 1,320 ($17.90) to GBX 1,000 ($13.56) and set a “hold” rating for the company in a research note on Thursday, November 9th. Finally, Numis Securities raised shares of Hikma Pharmaceuticals to a “buy” rating and set a GBX 1,300 ($17.63) target price for the company in a research note on Thursday, November 9th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company. Hikma Pharmaceuticals has an average rating of “Hold” and an average price target of GBX 1,171 ($15.88).

Hikma Pharmaceuticals (LON:HIK) opened at GBX 1,010.13 ($13.70) on Wednesday. Hikma Pharmaceuticals has a 1-year low of GBX 906.50 ($12.29) and a 1-year high of GBX 2,346 ($31.81). The stock has a market cap of $2,440.00 and a PE ratio of 1,980.65.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.themarketsdaily.com/2018/01/10/jefferies-group-lowers-hikma-pharmaceuticals-hik-to-underperform.html.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply